SHARPE
Reported results
- Cash, cash equivalents and marketable securities totaled $977.5 million as of September 30, 2026.
- Collaboration revenue was $0 for the three months ended September 30, 2026, compared to $53.8 million for the same period in 2025.
- Research and development expenses were $48.9 million for the three months ended September 30, 2026, compared to $30.8 million for the same period in 2025.
- General and administrative expenses were $29.2 million for the three months ended September 30, 2026, compared to $8.9 million for the same period in 2025.
- GAAP net loss for the three months ended September 30, 2026 was $68.4 million, or $0.39 per share (basic and diluted), compared to net income of $15.9 million in the same period in 2025.
Price and volatility reaction
The stock moved +5.8% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 21.5 | 2026-11-06 |
| Close after release | 22.74 | 2026-11-09 |
| Realised move | +5.8% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.